Dialogue between Medicines for Europe and Active Citizenship Network

Since 2017 Medicines for Europe, through its Value Added Medicines Group, and Cittadinanzattiva Onlus, through its international branch Active Citizenship Network, have decided to cooperate for a better access to healthcare across Europe and for a better respect of patients' rights, starting from the patients’ right of access to healthcare, the patients’ right to innovation and the patients’ right to personalized treatment. In particular:

• Active Citizenship Network was officially involved in the Value Added Medicines Exhibition “My Voice Matters!” at the EU Parliament (21-24 Nov, 2017);
• Active Citizenship Network was included in the panel of the 1st Value Added Medicines Conference (22 Nov, 2017 - Bruxelles);
• The Value Added Medicines Group was included in the panel of the XII European Patients’ Rights Day at the EU Parliament (23 May, 2018);
• Medicine for Europe is one of the supporters of the social media awareness campaign across Europe on Therapeutic Adherence promoted by Active Citizenship Network as follow up of the XII European Patients’ Rights Day (II° part of 2018/I° part of 2019);
• Active Citizenship Network was included in the panel of the 24th Medicines for Europe - 21st IGBA Annual Conference (13 - 15 June, 2018 - Budapest);
• Active Citizenship Network was officially included as expert in the evaluation committee of the Value Added Medicines Award 2018. In occasion of the 2nd Value Added Medicines conference in Brussels on November 21, 2018, ACN as a member of the jury awarded the winners. 
• EU workshop “Making Patients voice matter: the role of value added medicines” co-organized by Medicines for Europe and Active Citizenship Network opened to a selected number of patients’ associations in Bruxelles (20 November, 2018). Medicines for Europe offered all participants of the workshop a waived conference fee for the 2nd Value Added Medicines conference on 21 November, 2018, in order to learn more and to discuss the challenges and opportunities for value added medicines in Europe.